昆德尔奥索诊断

最新新闻

• 评级变动
  UBS Maintains QuidelOrtho(QDEL.US) With Hold Rating, Cuts Target Price to $12
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• 评级变动
  J.P. Morgan Maintains QuidelOrtho(QDEL.US) With Sell Rating, Cuts Target Price to $15
  \u5e02\u573a\u8d44\u8baf · 2026/4/17
• 公司公告
  4: QuidelOrtho | 4: Statement of changes in beneficial ownership of securities-Director Wilkins Joseph D Jr.
  SEC · 2026/6/30
• 评级变动
  William Blair Maintains QuidelOrtho(QDEL.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/4/16
• 评级变动
  Citi Maintains QuidelOrtho(QDEL.US) With Hold Rating, Raises Target Price to $18
  \u5e02\u573a\u8d44\u8baf · 2026/7/8
• 公司公告
  4: QuidelOrtho | 4: Statement of changes in beneficial ownership of securities-Director Michael Edward L.
  SEC · 2026/6/30
• 公司公告
  4: QuidelOrtho | 4: Statement of changes in beneficial ownership of securities-Director Michael Edward L.
  SEC · 2026/6/3
• 评级变动
  QuidelOrtho (QDEL) Receives a Sell From J.P. Morgan
  TipRanks · 2026/5/7
• J.P. Morgan Maintains QuidelOrtho(QDEL.US) With Sell Rating, Maintains Target Price $12
  \u5e02\u573a\u8d44\u8baf · 2026/8/24
• 公司公告
  4: QuidelOrtho | 4: Statement of changes in beneficial ownership of securities-Director Wilkins Joseph D Jr.
  SEC · 2026/6/3
• J.P. Morgan Sticks to Its Sell Rating for QuidelOrtho (QDEL)
  TipRanks · 2026/8/24
• 评级变动
  Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), Contineum Therapeutics, Inc. Class A (CTNM) and Schrodinger (SDGR)
  TipRanks · 2026/5/6
• QuidelOrtho Q2 Adj. EPS $0.13 Beats $(0.05) Estimate, Sales $631.000M Beat $618.849M Estimate
  Benzinga · 2026/8/7
• 评级变动
  Jefferies Downgrades QuidelOrtho(QDEL.US) to Hold Rating, Cuts Target Price to $12.5
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• 评级变动
  William Blair Maintains QuidelOrtho(QDEL.US) With Hold Rating, Announces Target Price $11.66
  \u5e02\u573a\u8d44\u8baf · 2026/5/6
• 评级变动
  Jefferies Maintains QuidelOrtho(QDEL.US) With Hold Rating, Maintains Target Price $12.5
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• 公司公告
  4: QuidelOrtho | 4: Statement of changes in beneficial ownership of securities-Director Michael Edward L.
  SEC · 2026/6/10
• Craig-Hallum Maintains QuidelOrtho(QDEL.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• J.P. Morgan Maintains QuidelOrtho(QDEL.US) With Sell Rating, Cuts Target Price to $12
  \u5e02\u573a\u8d44\u8baf · 2026/7/1
• 评级变动
  Citi Maintains QuidelOrtho(QDEL.US) With Hold Rating, Cuts Target Price to $13
  \u5e02\u573a\u8d44\u8baf · 2026/5/6

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。